0 Commentarii
0 Distribuiri
613 Views
0 previzualizare
Căutare
Descoperă oameni noi, creează noi conexiuni și faceti-va noi prieteni
-
Vă rugăm să vă autentificați pentru a vă dori, partaja și comenta!
-
Chronic Kidney Disease - Mineral Bone Disorders (CKD-MBD) Treatment Market Dynamics: Key Drivers and RestraintsFuture of Executive Summary Chronic Kidney Disease - Mineral Bone Disorders (CKD-MBD) Treatment Market: Size and Share Dynamics CAGR Value The global chronic kidney disease - mineral bone disorders (CKD-MBD) treatment market size was valued at USD 2.39 billion in 2024 and is expected to reach USD 4.80 billion by 2032, at a CAGR of 9.09% during the forecast...0 Commentarii 0 Distribuiri 4 Views 0 previzualizare
-
Global Hypertension in CKD Market to Surge to $11.5 Billion by 2032The "Hypertension in Chronic Kidney Disease (CKD) Market," according to Introspective Market Research has a highlighting rapid expansion fueled by the urgent need for comprehensive treatment strategies for this pervasive co-morbidity. The report projects that the global market, valued at an estimated $254.3 Million in 2023, is forecasted to grow substantially to...0 Commentarii 0 Distribuiri 512 Views 0 previzualizare
-
Blood Dialyzer Market: Projected to Reach $20.60 Billion by 2032Introspective Market Research (IMR) today released its detailed analysis of the Global Blood Dialyzer Market, projecting strong growth over the next decade. The report estimates that the market will grow from approximately USD 12.50 billion in 2023 to USD 20.60 billion by 2032, representing a compound annual growth rate (CAGR) of 5.80% during the forecast period. This growth is largely being...0 Commentarii 0 Distribuiri 1K Views 0 previzualizare
-
Is the Global EPO Drugs Market Expanding With Rising Chronic Kidney Disease and Anemia Cases?Executive Summary Erythropoietin (EPO) Drugs Market Size and Share Forecast The global erythropoietin (EPO) drugs market size was valued at USD 9.12 billion in 2024 and is expected to reach USD 22.60 billion by 2032, at a CAGR of 12.00% during the forecast period The Erythropoietin (EPO) Drugs report also makes available CAGR value fluctuation...0 Commentarii 0 Distribuiri 398 Views 0 previzualizare